T. Rowe Price Associates
CNTA

T. Rowe Price Associates’s Centessa Pharmaceuticals CNTA Stock Holding History

T. Rowe Price Associates’s Portfolio CNTA Stock Details CNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-3,927,343
Closed -$98.2M – 3149
2025
Q4 		$98.2M Sell
3,927,343
-876,713
-18% -$22.2M 0.01% 633
2025
Q3 		$116M Sell
4,804,056
-1,103,936
-19% -$19.6M 0.01% 587
2025
Q2 		$77.6M Buy
5,907,992
+565,648
+11% +$7.17M 0.01% 622
2025
Q1 		$76.8M Sell
5,342,344
-22,048
-0.4% -$361K 0.01% 604
2024
Q4 		$89.9M Buy
5,364,392
+685,371
+15% +$11.4M 0.01% 588
2024
Q3 		$74.8M Buy
4,679,021
+1,148,648
+33% +$14.1M 0.01% 634
2024
Q2 		$31.9M Buy
3,530,373
+572,294
+19% +$5.43M ﹤0.01% 844
2024
Q1 		$33.4M Buy
2,958,079
+418,615
+16% +$3.96M ﹤0.01% 826
2023
Q4 		$20.2M Sell
2,539,464
-9,670
-0.4% -$64.8K ﹤0.01% 952
2023
Q3 		$16.5M Buy
2,549,134
+185,923
+8% +$1.27M ﹤0.01% 961
2023
Q2 		$14.6M Buy
2,363,211
+49,778
+2% +$236K ﹤0.01% 1014
2023
Q1 		$8.91M Sell
2,313,433
-73,734
-3% -$270K ﹤0.01% 1079
2022
Q4 		$7.4M Sell
2,387,167
-58,816
-2% -$218K ﹤0.01% 1104
2022
Q3 		$9.83M Sell
2,445,983
-15,147
-0.6% -$69.3K ﹤0.01% 1069
2022
Q2 		$12M Sell
2,461,130
-67,453
-3% -$432K ﹤0.01% 1292
2022
Q1 		$22.7M Buy
2,528,583
+451,813
+22% +$4.12M ﹤0.01% 1202
2021
Q4 		$23.4M Buy
2,076,770
+58,897
+3% +$792K ﹤0.01% 1247
2021
Q3 		$33.1M Buy
2,017,873
+6,800
+0.3% +$141K ﹤0.01% 1157
2021
Q2 		$43.9M Buy
+2,011,073
New +$47.3M ﹤0.01% 1071

Other funds holding CNTA

MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
IVLAV
Index Venture Life Associates VI St. Helier, Jersey $396M AUM 176.22% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

T. Rowe Price Associates's CNTA Position: Q1 2026 in Review

T. Rowe Price Associates sold out of Centessa Pharmaceuticals (CNTA) in Q1 2026, closing a stake of 3,927,343 shares — an estimated $98.2M sold.

T. Rowe Price Associates first reported a position in CNTA in Q2 2021 and held it in 19 quarters. The position peaked at $116M in Q3 2025. 161 funds tracked by Wall St. Rank hold CNTA as of Q1 2026.

  • T. Rowe Price Associates reported no remaining Centessa Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • T. Rowe Price Associates sold 3,927,343 Centessa Pharmaceuticals shares in Q1 2026, an estimated $98.2M.
  • T. Rowe Price Associates first reported a position in Centessa Pharmaceuticals in Q2 2021 and held it in 19 quarters.
  • T. Rowe Price Associates's Centessa Pharmaceuticals position peaked at $116M in Q3 2025.
  • 161 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.